BARD1 and breast cancer in Poland

[1]  A. Jakubowska,et al.  CHEK2-Positive Breast Cancers in Young Polish Women , 2006, Clinical Cancer Research.

[2]  J. Kere,et al.  Nordic collaborative study of the BARD1 Cys557Ser allele in 3956 patients with cancer: enrichment in familial BRCA1/BRCA2 mutation-negative breast cancer but not in other malignancies , 2006, Journal of Medical Genetics.

[3]  J. Gulcher,et al.  The BARD1 Cys557Ser Variant and Breast Cancer Risk in Iceland , 2006, PLoS medicine.

[4]  W. Kozlowski,et al.  BRCA1-positive breast cancers in young women from Poland , 2006, Breast Cancer Research and Treatment.

[5]  A. Jakubowska,et al.  Breast cancer predisposing alleles in Poland , 2005, Breast Cancer Research and Treatment.

[6]  J. Lubiński,et al.  CHEK2 is a multiorgan cancer susceptibility gene. , 2004, American journal of human genetics.

[7]  A. Jakubowska,et al.  A high proportion of founder BRCA1 mutations in Polish breast cancer families , 2004, International journal of cancer.

[8]  Maria Chosia,et al.  Germline 657del5 mutation in the NBS1 gene in breast cancer patients , 2003, International journal of cancer.

[9]  Nazneen Rahman,et al.  Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002, Nature Genetics.

[10]  Anne M. Bowcock,et al.  Identification of a RING protein that can interact in vivo with the BRCA1 gene product , 1996, Nature Genetics.

[11]  Julian Peto,et al.  Identification of the breast cancer susceptibility gene BRCA2 , 1996, Nature.

[12]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[13]  D. Lahiri,et al.  DNA isolation by a rapid method from human blood samples: Effects of MgCl2, EDTA, storage time, and temperature on DNA yield and quality , 1993, Biochemical Genetics.

[14]  M. Swift,et al.  Breast and other cancers in families with ataxia-telangiectasia. , 1987, The New England journal of medicine.

[15]  The Polish Breast Cancer Consortium.  Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002 .